ASCO GI – Jazz sees a new Ziihera Herizon
But Tevimbra’s role looks shaky as adverse events loom.
Instil’s bispecific dream is over
The company hands its PD-L1 x VEGF bispecific back to ImmuneOnco.
FDA red and green lights: December 2025
Seven oncology approvals included nods for subcutaneous Rybrevant and Lunsumio.
Henlius and Ottimo join the bispecific bundle
Two new PD-(L)1 x VEGF projects have entered the clinic.
SABCS 2025 – pumitamig replicates breast cancer findings
Global phase 2 data in TNBC look similar to earlier results in China.
ASH 2025 – Regeneron’s Lynozyfic shows front-line promise
Linker-MM4 data raise more questions about sequencing of therapies for multiple myeloma.
ASH 2025 – J&J’s multiple myeloma juggling act
Tecvayli plus Darzalex could challenge Carvykti in the push for a functional cure.
Crescent moves to close the bispecific gap
Cross-licensing pact brings in SKB105, and hands off China rights to CR-001 before first-in-human studies.
J&J tries to outdo Tecvayli
With a phase 3 trial of the trispecific T-cell engager ramantamig, J&J will challenge itself.
Janux lets the genie out of the bottle
A more comprehensive dataset on JANX007 sends the group’s stock down.
